
- Vol 30 No 6
- Volume 30
- Issue 6
The Paradox of Choice: When More Medications Mean Less Treatment
Two problems persist in the treatment of severe mental illness that constitute a barrier to effective patient-centered care: excessive reliance on a limited number of antipsychotic medications at the expense of other effective treatments, and the underutilization of other evidence-based treatment options.
Dr Barkil-Oteo will be presenting on the topic presented in this article at the
This is an exciting time in health care, with a
In particular, 2 problems persist in the treatment of severe mental illness that constitute a barrier to effective patient-centered care: excessive reliance on a limited number of antipsychotic medications at the expense of other effective treatments, and the underutilization of other evidence-based treatment options.
In 2009 Philip Wang, MD, PhD, current Deputy Director of the National Institute of Mental Health, and colleagues,2
The exorbitant cost of antipsychotic medications may change, given that 2 out of the 3 medications (Zyprexa and Seroquel) are in the process of becoming available in generic forms. However, there is no guarantee that the savings will be directed to other treatment modalities in mental health, and recent trends in the pharmaceutical industry indicate that the manufacturers of generic medications are consolidating: Such reduced competition could lead to sustained high prices for generics in the future. As of 2010,
Some evidence-based approaches to chronic mental illness (CBT groups for psychotic symptoms, supported employment, family psychoeducation, and supported housing programs, among others) are underutilized. For example, in the 1990s, the
Limited treatment choices jeopardize our ability to meaningfully include people in deciding their treatment. The values of people with mental illness cannot be incorporated if they don’t have a choice of treatment because in many cases they are offered few highly similar options. A meaningful choice experience should include options that are significantly different but complementary; deciding between 2 similar options provides only the illusion of choice. Instead, the process should be based on a collaborative approach, one balanced with the provision of informed choices and the offer of all evidence-based alternatives. Persons with mental illness, like every member of society,
Psychiatrists should be aware of the unintended consequences that may result from current patterns of spending in the mental health sector. Mental health professionals should advocate for evidence-based, rational use of medications (both generic and brand label) to encourage the most efficient use of resources. In a discussion of evidence-based practices in mental health, Essock and colleagues12
People do not survive on antipsychotics alone. Rather, they are sustained by positive coping mechanisms, a home, a job, and meaningful social interactions. When served with alternatives, people will not accept interventions that they do not want. Provision of new, expensive medications as the sole option for treatment should not take the place of delivering comprehensive care. In an era of patient-centered medicine, patient choice should be highly valued. The right to receive all evidence-based interventions, both pharmacological and psycho-social, must be assured. In order to facilitate a broader range of medical and psychosocial interventions, psychiatrists should play 2 important roles in the current mental health system: as guides in the selection of evidence-based treatments that match patients’ values; and as advocates for the most efficient use of resources.
Articles in this issue
over 12 years ago
The Family Guide to Mental Health Careover 12 years ago
“PRN” Medication for Alcohol Dependence May Reduce Harmover 12 years ago
No Mortality Increase With Antipsychotics in Prospective Studyover 12 years ago
Epidemiology and Treatment of Substance Use and Abuse in Adolescentsover 12 years ago
Bias Against Schizophrenic Patients Seeking Medical Careover 12 years ago
Pain and Suicideover 12 years ago
Shared Risk Factors in Multiple Psychiatric Disordersover 12 years ago
Genetics and Pharmacogenetics of Schizophrenia: Recent ProgressNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.